Replicative Adenovirus Vector (RGDCRAdCOX2F)

N/A

Report date: 2024/11/20 20:00:31

Base Information

Drug NameReplicative Adenovirus Vector (RGDCRAdCOX2F)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMasonic Cancer Center, University Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A